Estrogen therapy has been reported to cause multiple alterations in he
mostasis and to increase blood levels of several procoagulants, includ
ing Hageman factor [factor XII (FXII)]. Liver FXII gene expression has
been investigated in ovariectomized rats, treated or not with 17 beta
-estradiol. A 6-fold stimulation of FXII gene transcription was observ
ed in treated compared to untreated animals, indicating that 17 beta-e
stradiol is able to induce FXII gene expression in vivo. We have recen
tly shown that human FXII promoter contains an imperfect palindrome, 5
'-GGGCAnnnTGACC-3' at position -43/-31 resembling the consensus estrog
en-responsive element (ERE). Portions of different length of the FXII
promoter were fused to the chloramphenicol acetyltransferase (CAT) cod
ing sequence and transiently cotransfected with human estrogen recepto
r (ER) into NIH3T3 and HepGa cells in the presence or absence of 17 be
ta-estradiol. A 230-base pair fragment of FXII promoter, spanning nucl
eotides -181/49, conferred a strong estrogen responsiveness to the CAT
reporter gene, suggesting that a functional ERE resides in this regio
n. Cognate receptors, such as those for thyroid hormone or retinoic ac
id, did not stimulate CAT activity. Gel mobility assays demonstrated a
specific interaction between ER and the 230-bp FXII promoter fragment
containing the putative ERE palindrome. Similar results were obtained
when an oligonucleotide spanning the consensus ERE was used; the comp
lex between ER and FXII promoter sequences was supershifted after the
addition of an anti-ER monoclonal antibody. Insertion of FXII-ERE into
the heterologous thymidine kinase promoter conferred a strong estroge
n responsiveness that was abolished by mutations of the 5'-half of the
palindrome. These results represent the first demonstration at the mo
lecular level of the regulation of a blood coagulation factor gene by
17 beta-estradiol as well as the first identification of a functional
ERE within this class of genes.